ALPPS
Cross-source consensus on ALPPS from 1 sources and 6 claims.
1 sources · 6 claims
Uses
Risks & contraindications
Comparisons
Highlighted claims
- ALPPS had significantly greater FLR gain than two-stage hepatectomy with PVEfLR in a Scandinavian multicentre randomised controlled trial. — Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review
- ALPPS complication rates are substantially higher than PVEfLR and the comprehensive complication index is significantly higher. — Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review
- ALPPS achieves larger and faster standardised FLR increases than PVEfLR. — Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review
- Median overall survival differences between ALPPS and PVEfLR across studies were not statistically significant. — Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review
- In-hospital mortality rates were not significantly different between PVEfLR and ALPPS. — Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review
- ALPPS is sometimes used as salvage therapy when patients fail to progress to resection after PVE. — Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review